Susceptibility of 497 clinical isolates of Gram-negative anaerobes to trovafloxacin and eight other antibiotics

Journal of Chemotherapy

Volumn 11, Issue 5, 1999, Pages 349-356

  Rotimi, Vincent O ^a   Mokaddas, E M ^b   Jamal, W Y ^a   Khodakhast, F B ^a   Verghese, T L ^a   Sanyal, S C ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b NONE

Author keywords

Anaerobic bacteria; Antibiotic susceptibility; Clinical isolates; Kuwait; Trovafloxacin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CARBAPENEM; CEFOXITIN; CLINDAMYCIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TROVAFLOXACIN;

ANAEROBIC INFECTION; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEROIDES FRAGILIS; CONTROLLED STUDY; GRAM NEGATIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVOTELLA;

EID: 0032733594     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.5.349     Document Type: Article

References (26)

1. Greenwood D. Sixty years on: antimicrobial drug resistance comes of age. Lancet 1995; 346: S1.
2. Neu H. Emerging trends in antimicrobial resistance in surgical infections. Eur J Surg 1994; 573: 7-18.
3. Finegold SM. Anaerobic infections in humans: an overview. Anaerobe 1995; 1: 3-9.
4. Finegold SM, and the National Committee for Clinical Laboratory Standards Working Group on Anaerobic Susceptibility Testing. Susceptibility testing of anaerobic bacteria. J Clin Microbiol 1988; 26: 1253-6.
5. Finegold SM. Anaerobes; problems and controversies in bacteriology, infections, and susceptibility testing. Rev Infect Dis 1990; 12: 233-40.
6. 6 Tally FP, Cuchural GJ Jr, Jacobus NV, et al. Susceptibility of Bacteroides fragilis group in the United States in 1981. Antimicrob Agents Chemother 1983; 23: 536-40.
7. Tally FP, Cuchural GC Jr, Jacobus NV, et al. Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States. Antimicrob Agents Chemother 1985; 28: 675-7.
8. Garcia-Rodriguez JE, Garcia-Sanchez JE. Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain. Rev Infect Dis 1990; 12: 142-51.
9. Dubreuil L, Devos J, Neut C, Romond C. Susceptibility of anaerobic bacteria from several hospitals to three major antibiotics. Antimicrob Agents Chemother 1984; 25: 764-6.
10. Watanabe K, Ueno K, Kato N, et al. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan. Eur J Clin Microbiol Infect Dis 1992; 11: 1069-73.
11. Rotimi VO, Khourshid M, Brazier JS, Jamal WY, Khodakhast FB. Bacteroides species highly resistant to metronidazole: an emerging clinical problem? Clin Microbiol Infect 1999; 5: 166-9.
12. Jacobs MR, Spangler SK, Appelbaum PC. Beta-lactamase production and susceptibility of US and European anaerobic Gram-negative bacilli to beta-lactams and other agents. Eur J Clin Microbiol Infect Dis 1992, 11: 1081-93.
13. Rotimi VO, Khodakhast FB, Jamal WY, Mokaddas EM. Activity of β-lactam antimicrobial agents against clinical isolates of Bacteroides fragilis in Kuwait. Clin Microbiol Infect 1998; 4: 728-730.
14. th edition), Star Publishing Company, 1993.
15. National Committee for Clinical Laboratory Standards. Method for antimicrobial susceptibility testing of anaerobic bacteria. Approved Standard M11-A3. Villanova: NCCLS, 1993.
16. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother 1994; 38: 2471-2476.
17. Wexler HM, Molitoris E, Molitoris D, Finegold SM. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother 1996; 40: 2232-2235.
18. Citron DM, Appleman MD. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. Antimicrob Agents Chemother 1997; 41: 2312-2316.
19. Cuchural GL Jr, Malamy MH, Tally RP. β-lactamase mediated imipenem resistance in Bacteroides fragilis. Antimicrob Agents Chemother 1986; 30: 645-9.
20. Bandoh K, Muto Y, Watanabe K, Katoh N, Ueno K. Biochemical properties and purification of metallo-β-lactamase from Bacteroides fragilis. Antimicrob Agents Chemother 1991; 35: 371-2.
21. Bandoh K, Watanabe K, Muto Y, Katoh N, Ueno K. Conjugal transfer of imipenem resistance in Bacteroides fragilis. J Antibiot 1992; 45: 542-7.
22. Fox AR, Phillips I. The antibiotic sensitivity of Bacteroides fragilis group in the United Kingdom. J Antimicrob Chemother 1987; 20: 477-488.
23. Phillips I, King A, Nord CE, Hoffstedt B and European Study Group. Antibiotic sensitivity of the Bacteroides fragilis group in Europe. Eur J Clin Microbiol Infect Dis 1992; 11: 292-304.
24. Breuil J, Burnat C, Patey O, Dublanchet A. Survey of Bacteroides fragilis susceptibility patterns in France. J Antimicrob Chemother 1989; 24: 69-75.
25. Betriu C, Cabronero C, Gomes M, Picazo JJ. Changes in the susceptibility of Bacteroides fragilis group of organisms to various antimicrobial agents 1979-89. Eur J Clin Microbiol Infect Dis 1992; 11: 352-356.
26. Stark CA, Edlund C, Sjostedt S, Kristensen G, Nord CE. Antimicrobial resistance in human oral and intestinal anaerobic microfloras. Antimicrob Agents Chemother 1993; 37: 1665-1669.